Determination 2 – Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

​ Conditions: Multiple Myeloma

Interventions: Drug: Isatuximab; Drug: Iberdomide; Drug: Bortezomib (B); Drug: Dexamethasone; Drug: Melphalan; Drug: Linvoseltamab; Device: On Body Delivery System (OBDS)

Sponsors: Dana-Farber Cancer Institute; Sanofi; Bristol-Myers Squibb; Celgene Corporation; Regeneron Pharmaceuticals

Not yet recruiting Conditions: Multiple Myeloma
Interventions: Drug: Isatuximab; Drug: Iberdomide; Drug: Bortezomib (B); Drug: Dexamethasone; Drug: Melphalan; Drug: Linvoseltamab; Device: On Body Delivery System (OBDS)
Sponsors: Dana-Farber Cancer Institute; Sanofi; Bristol-Myers Squibb; Celgene Corporation; Regeneron Pharmaceuticals
Not yet recruiting